Medi Caps (523144)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Trading at ~0.83x book value with book value at ₹58.60 versus price ₹48.57, offering a margin of safety if asset values are real.
• Sales growth of 6.97% shows some top-line traction despite weak profitability.
• Piotroski F-Score of 6/9 suggests moderate financial health across profitability, leverage, and efficiency signals.
• Recent price at ₹48.57 near the top of the 52-week range ₹21.00-₹48.57, indicating renewed market interest.

Concerns

• Latest quarter is loss-making: sales of ₹4 Cr and net profit of -₹1 Cr, so current operations are not generating shareholder value.
• ROE of 1.30% and ROCE of -2.12% reflect very poor returns on capital employed.
• P/E is 0.00 and dividend yield is zero, with no current earnings or income support for the valuation.
• Insufficient data: promoter holding and debt/equity are N/A, making governance and leverage risk unassessable.

AI Analysis

Looking at Medi Caps, I'm reminded that a low price-to-book is not by itself a bargain. The stock trades at ₹48.57, below book value of ₹58.60, so the market is offering this business at 83 paise per rupee of net assets. But a Benjamin Graham disciple must ask: can these assets generate earnings? The latest quarter tells a troubling story: sales of just ₹4 Cr and a net loss of ₹1 Cr. Full-year ROE is a meager 1.30% and ROCE is negative at -2.12%, meaning operating capital is destroying value, not creating it. A P/E of 0.00 confirms that current earnings are essentially absent. There is 6.97% sales growth and reported profit growth of 62.44%, but with such a small base and a loss in the latest quarter, I would not anchor on that figure. The Piotroski F-score of 6/9 gives me some comfort that the financial position is not collapsing, yet I need to know much more about debt, promoter holding, and why earnings are so weak. At a ₹61 Cr market cap, this is a micro-cap in a competitive pharma world; a durable moat is not visible from these numbers. If assets are genuinely worth ₹58.60 and can be unlocked, this could be an asset play. But if those assets earn poor returns, book value can erode. I would need a long track record of cash generation and honest capital allocation before committing. For now, it is a possible asset-backed opportunity, not a wonderful compounder.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer